Literature DB >> 27613713

From the Cover: Coagulation-Driven Hepatic Fibrosis Requires Protease Activated Receptor-1 (PAR-1) in a Mouse Model of TCDD-Elicited Steatohepatitis.

Rance Nault1,2, Kelly A Fader1,2, Anna K Kopec2,3, Jack R Harkema3, Timothy R Zacharewski1,2, James P Luyendyk4,3.   

Abstract

Emerging evidence supports a role for environmental chemical exposure in the pathology of non-alcoholic fatty liver disease (NAFLD), a disease process tightly linked to increased activity of the blood coagulation cascade. Exposure of C57BL/6 mice to the persistent environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) recapitulates features of the NAFLD spectrum, including steatosis, hepatic injury, inflammation, and fibrosis. We assessed coagulation cascade activation, and determined the role of the thrombin receptor protease activated receptor-1 (PAR-1) in experimental TCDD-elicited NAFLD. Chronic exposure to TCDD (30 µg/kg every 4 days for 28 days) was associated with intrahepatic coagulation, indicated by increased plasma thrombin-antithrombin levels and hepatic fibrin(ogen) deposition. PAR-1 deficiency diminished TCDD-elicited body weight loss and relative liver weight was reduced in TCDD-exposed PAR-1-/- mice compared with TCDD-exposed wild-type mice. PAR-1 deficiency did not affect TCDD-induced hepatic steatosis or hepatocellular injury, as indicated by serum alanine aminotransferase activity. Despite a lack of effect on these 2 features of NAFLD pathology, PAR-1 deficiency was associated with a reduction in hepatic inflammation evident in liver histopathology, and reflected by a reduction in serum levels of the proinflammatory cytokine interleukin-6. Moreover, TCDD-driven hepatic collagen deposition was markedly reduced in PAR-1-deficient mice. These results indicate that experimental TCDD-elicited steatohepatitis is associated with coagulation cascade activation and PAR-1-driven hepatic inflammation and fibrosis.
© The Author 2016. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Coagulation; Fibrosis; NAFLD.; PAR-1; TCDD

Mesh:

Substances:

Year:  2016        PMID: 27613713      PMCID: PMC5139072          DOI: 10.1093/toxsci/kfw175

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  37 in total

1.  The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis.

Authors:  Bradley P Sullivan; Paul H Weinreb; Shelia M Violette; James P Luyendyk
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Authors:  A Phillip Owens; Freda H Passam; Silvio Antoniak; Stephanie M Marshall; Allison L McDaniel; Lawrence Rudel; Julie C Williams; Brian K Hubbard; Julie-Ann Dutton; Jianguo Wang; Peter S Tobias; Linda K Curtiss; Alan Daugherty; Daniel Kirchhofer; James P Luyendyk; Patrick M Moriarty; Shanmugam Nagarajan; Barbara C Furie; Bruce Furie; Douglas G Johns; Ryan E Temel; Nigel Mackman
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 3.  From the metabolic syndrome to NAFLD or vice versa?

Authors:  Ester Vanni; Elisabetta Bugianesi; Anna Kotronen; Samuele De Minicis; Hannele Yki-Järvinen; Gianluca Svegliati-Baroni
Journal:  Dig Liver Dis       Date:  2010-03-06       Impact factor: 4.088

4.  Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.

Authors:  Anna K Kopec; Nikita Joshi; Keara L Towery; Karen M Kassel; Bradley P Sullivan; Matthew J Flick; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-08-19       Impact factor: 4.030

5.  Mice lacking the thrombin receptor, PAR1, have normal skin wound healing.

Authors:  A J Connolly; D Y Suh; T K Hunt; S R Coughlin
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

6.  Toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in C57B1/6 mice.

Authors:  J G Vos; J A Moore; J G Zinkl
Journal:  Toxicol Appl Pharmacol       Date:  1974-08       Impact factor: 4.219

7.  Toxicogenomic evaluation of long-term hepatic effects of TCDD in immature, ovariectomized C57BL/6 mice.

Authors:  Anna K Kopec; Darrell R Boverhof; Rance Nault; Jack R Harkema; Colleen Tashiro; Dave Potter; Bonnie Sharratt; Brock Chittim; Timothy R Zacharewski
Journal:  Toxicol Sci       Date:  2013-07-17       Impact factor: 4.849

8.  Quantifying hepatic steatosis - more than meets the eye.

Authors:  Adam P Levene; Hiromi Kudo; Matthew J Armstrong; Mark R Thursz; Wladyslaw M Gedroyc; Quentin M Anstee; Robert D Goldin
Journal:  Histopathology       Date:  2012-02-28       Impact factor: 5.087

Review 9.  Evaluation of the association between persistent organic pollutants (POPs) and diabetes in epidemiological studies: a national toxicology program workshop review.

Authors:  Kyla W Taylor; Raymond F Novak; Henry A Anderson; Linda S Birnbaum; Chad Blystone; Michael Devito; David Jacobs; Josef Köhrle; Duk-Hee Lee; Lars Rylander; Anna Rignell-Hydbom; Rogelio Tornero-Velez; Mary E Turyk; Abee L Boyles; Kristina A Thayer; Lars Lind
Journal:  Environ Health Perspect       Date:  2013-05-07       Impact factor: 9.031

10.  Proteinase activated receptor 1 mediated fibrosis in a mouse model of liver injury: a role for bone marrow derived macrophages.

Authors:  Yiannis N Kallis; Christopher J Scotton; Alison C Mackinnon; Robert D Goldin; Nicholas A Wright; John P Iredale; Rachel C Chambers; Stuart J Forbes
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more
  14 in total

1.  Chronic liver injury drives non-traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase.

Authors:  L G Poole; A Pant; K S Baker; A K Kopec; H M Cline-Fedewa; S E Iismaa; M J Flick; J P Luyendyk
Journal:  J Thromb Haemost       Date:  2018-12-10       Impact factor: 5.824

2.  Lipidomic Evaluation of Aryl Hydrocarbon Receptor-Mediated Hepatic Steatosis in Male and Female Mice Elicited by 2,3,7,8-Tetrachlorodibenzo-p-dioxin.

Authors:  Rance Nault; Kelly A Fader; Todd A Lydic; Timothy R Zacharewski
Journal:  Chem Res Toxicol       Date:  2017-03-20       Impact factor: 3.739

Review 3.  Role of the blood coagulation cascade in hepatic fibrosis.

Authors:  Asmita Pant; Anna K Kopec; James P Luyendyk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-05-03       Impact factor: 4.052

Review 4.  Persistent Endocrine-Disrupting Chemicals and Fatty Liver Disease.

Authors:  Andrea L Deierlein; Sarah Rock; Sally Park
Journal:  Curr Environ Health Rep       Date:  2017-12

5.  Loss of liver-specific and sexually dimorphic gene expression by aryl hydrocarbon receptor activation in C57BL/6 mice.

Authors:  Rance Nault; Kelly A Fader; Jack R Harkema; Tim Zacharewski
Journal:  PLoS One       Date:  2017-09-18       Impact factor: 3.240

6.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) dysregulates hepatic one carbon metabolism during the progression of steatosis to steatohepatitis with fibrosis in mice.

Authors:  Russell R Fling; Claire M Doskey; Kelly A Fader; Rance Nault; Tim R Zacharewski
Journal:  Sci Rep       Date:  2020-09-09       Impact factor: 4.379

Review 7.  The Role of Anticoagulation in Treating Portal Hypertension.

Authors:  Laura Turco; Filippo Schepis; Erica Villa
Journal:  Curr Hepatol Rep       Date:  2018-06-18

8.  Liver fibrosis is driven by protease-activated receptor-1 expressed by hepatic stellate cells in experimental chronic liver injury.

Authors:  Lauren G Poole; Asmita Pant; Holly M Cline-Fedewa; Kurt J Williams; Bryan L Copple; Joseph S Palumbo; James P Luyendyk
Journal:  Res Pract Thromb Haemost       Date:  2020-06-25

Review 9.  Coagulation, Microenvironment and Liver Fibrosis.

Authors:  Niccolò Bitto; Eleonora Liguori; Vincenzo La Mura
Journal:  Cells       Date:  2018-07-24       Impact factor: 6.600

10.  Protease-activated receptor-1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy.

Authors:  Maaike Waasdorp; Dennis M de Rooij; Sandrine Florquin; JanWillem Duitman; C Arnold Spek
Journal:  J Cell Mol Med       Date:  2018-11-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.